Corrigendum to “What is the impact and efficacy of routine immunological, biochemical and hematological biomarkers as predictors of COVID-19 mortality?” [Int. Immunopharmacol. 105 (2022) 108542] (International Immunopharmacology (2022) 105, (S1567576922000261), (10.1016/j.intimp.2022.108542))

CorrectionAçık Erişim

Özet

The authors express their apologies for the minor errors mentioned below. First, the authors misidentified the significant p-values they show in Tables 1–8. Second, they miscalculated the 95% CI breakpoints of the PT value in Table 7. The authors report that the level of significance for p = 0.000 in Tables 1–8 is p < 0.001. They also state that the 95% CI values of the PT parameter specified in Table 7 are 1.63-2.56. These corrections do not affect the interpretation of the data or the conclusions drawn. The authors apologize to the journal and readers for these unintentional errors. © 2023 Elsevier B.V.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/11873Resmi atıflarda kullanılan kalıcı adres
Tam Kayıt
AlanDeğerDil
dc.contributor.authorHuyut, Mehmet Tahir
dc.contributor.authorHuyut, Zübeyir
dc.contributor.authorIlkbahar, Fatih
dc.contributor.authorMertoğlu, Cuma
dc.date.accessioned2026-10-18T20:26:51.892438144Z
dc.date.available2026-10-18T20:26:51.892438144Z
dc.date.issued2023
dc.description.abstractThe authors express their apologies for the minor errors mentioned below. First, the authors misidentified the significant p-values they show in Tables 1–8. Second, they miscalculated the 95% CI breakpoints of the PT value in Table 7. The authors report that the level of significance for p = 0.000 in Tables 1–8 is p < 0.001. They also state that the 95% CI values of the PT parameter specified in Table 7 are 1.63-2.56. These corrections do not affect the interpretation of the data or the conclusions drawn. The authors apologize to the journal and readers for these unintentional errors. © 2023 Elsevier B.V.
dc.identifier.doi10.1016/j.intimp.2023.110821
dc.identifier.eissn1878-1705
dc.identifier.issn1567-5769
dc.identifier.pmcidPMC11021217
dc.identifier.pmid37625945
dc.identifier.scopus2-s2.0-85168748208
dc.identifier.startpage110821
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/11873
dc.identifier.volume123
dc.identifier.wosWOS:001083709600001
dc.language.isoen
dc.publisherElsevier B.V.
dc.relation.ispartofInternational Immunopharmacology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjecterratum
dc.titleCorrigendum to “What is the impact and efficacy of routine immunological, biochemical and hematological biomarkers as predictors of COVID-19 mortality?” [Int. Immunopharmacol. 105 (2022) 108542] (International Immunopharmacology (2022) 105, (S1567576922000261), (10.1016/j.intimp.2022.108542))
dc.typeCorrection
dspace.entity.typePublication
rdl.citation.scopus0
rdl.citation.wos0
rdl.departmentErzincan Binali Yıldırım University, Faculty of Medicine, Department of Biostatistics and Medical Informatics, Erzincan, Türkiye. Electronic address: tahir.huyut@erzincan.edu.tr. | Erzincan Binali Yıldırım University, Faculty of Medicine, Department of Clinical Biochemistry, Erzincan, Türkiye
rdl.departmentInonu University, Faculty of Medicine, Department of Clinical Biochemistry, Malatya, Türkiye.
rdl.oa.statusgreen
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)